ArticleMolecular cancer therapeutics2015
Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach.
Article in Molecular cancer therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Circulating Tumour Cells as Prognostic Biomarkers in Colorectal Cancer: A Systematic Review.International journal of molecular sciences · 2021Pooled it
- Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients.The pharmacogenomics journal · 2018Trial
- Article
- Survival mechanisms of circulating tumor cells and their implications for cancer treatment.Cancer metastasis reviews · 2024Review
- Review
- Review
- Utilization of Circulating Tumor Cells in the Management of Solid Tumors.Journal of personalized medicine · 2023Review
- Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'?British journal of cancer · 2022Review
- Review
- Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex.Journal of experimental & clinical cancer research : CR · 2020Article
- Development and validation of an individualized gene expression-based signature to predict overall survival in metastatic colorectal cancer.Annals of translational medicine · 2020Article
- Shear stress activates ATOH8 via autocrine VEGF promoting glycolysis dependent-survival of colorectal cancer cells in the circulation.Journal of experimental & clinical cancer research : CR · 2020Article
- Six-gene Assay as a new biomarker in the blood of patients with colorectal cancer: establishment and clinical validation.Molecular oncology · 2019Article
- Circulating Tumour Cells, Circulating Tumour DNA and Circulating Tumour miRNA in Blood Assays in the Different Steps of Colorectal Cancer Management, a Review of the Evidence in 2019.BioMed research international · 2019Review
- Survival Mechanisms and Influence Factors of Circulating Tumor Cells.BioMed research international · 2018Review
- Identification of relevant prognostic values of cytokeratin 20 and cytokeratin 7 expressions in lung cancer.Bioscience reports · 2017Article
- Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons.Current colorectal cancer reports · 2016Article
- Identifying cancer origin using circulating tumor cells.Cancer biology & therapy · 2016Article
- Circulating Tumor Cells Expressing Krüppel-Like Factor 8 and Vimentin as Predictors of Poor Prognosis in Pancreatic Cancer Patients.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
Circulating tumor cells (CTC) express epithelial and stem cell-like genes, though current approved detection methods mainly use epithelial markers. We optimized a CTC isolation method that could capture their molecular heterogeneity and predict overall survival (OS) in metastatic colorectal cancer (mCRC) patients receiving various chemotherapy regimens. We combined immunomagnetic enrichment of CD45-negative, EpCAM-positive circulating cancer cells with qRT-PCR amplification of CK20 and survivin expression in 88 mCRC patients and 20 healthy controls. We then evaluated the prognostic value of baseline CTC CK20 and survivin expression in mCRC patients. The presence of elevated CTC CK20 or survivin expression distinguished mCRC patients from controls with sufficient sensitivity (79.6%) and specificity (85%). In univariate analysis, patients with high CTC-CK20 expression (9 vs. 33.2+ months, log-rank P < 0.001) or high CTC-survivin expression (10 vs. 33.2+ months, log-rank P = 0.032) had a significantly worse median OS than those with low expression of either marker. In multivariable analysis, the high CTC-CK20 group had significantly shortened OS (HR, 3.11; adjusted P = 0.01), and there was a trend toward inferior OS in the high CTC-survivin group (HR, 1.76; adjusted P = 0.099). Patients with either high CTC CK20 or survivin expression had inferior OS compared with those with low expression of both markers (HR, 4.39; 95% confidence interval, 1.56-12.35; adjusted P = 0.005). Colorectal cancer CTCs can be reliably isolated using epithelial and stem cell markers. CTC CK20 and survivin expression may effectively predict OS in mCRC patients receiving chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.